Eph receptor tyrosine kinases (Ephs) and their membrane-anchored ligands (ephrins) form a vital cell communication system capable of bi-directional signaling. This Eph receptor/ephrin system has classically been demonstrated to play a role in development. However, emerging evidence has revealed differential expression of Ephs and ephrins in numerous cancers. Recent studies suggest that this system influences invasive behaviour, promoting a more aggressive and metastatic phenotype. Hence, this minireview summarizes the current understanding of the contribution of both Eph receptors and their ephrin ligands to invasiveness in cancer, as well as their use as potential therapeutic targets.
Eph receptors have been divided into an EphA subclass (8 members) and an EphB subclass (6 members) on the basis of sequence similarity and ligand affinity (Gale et. al., 1996) . Ephrin ligands have also been divided into two subclasses: GPI-linked ephrin As (5 members) and transmembrane ephrin Bs (3 members). Although promiscuity has been observed, the ephrin A ligands preferentially bind to EphA receptors, while ephrin B ligands bind preferentially to EphB receptors (Heroult et. al., 2006) .
The Eph receptor/ephrin system has been demonstrated to play a role in numerous biological processes. Generally, Ephs and ephrins are thought to act as graded molecular tags which translate the density of their cognate partner on opposing membranes into precisely graded cellular responses, resulting in cellcontact repulsion or cell-cell adhesion. Through this mechanism, the Eph receptor/ephrin system has been shown to direct the positioning, adhesion and migration of cells and cell layers during development (WimmerKleikamp and Lackmann, 2005) . This system has also been implicated in immune regulation (Wu and Luo, 2005) , as well as in central nervous system injury and disease (Goldshmit et. al., 2006) . Recently, a role for the Eph receptor/ephrin system has also emerged in cancer, especially in the area of invasive behaviour.
to be accompanied by upregulation of ephrin B1 and downregulation of EphB4 (Red-Horse et. al., 2005) . Additionally, ephrin A5 expression was found to increase invasive behaviour, anchorage-independent growth, and morphological transformation of murine fibroblasts (Campbell et. al., 2006) .The majority of research on Ephs and ephrins in invasion, however, has focused on their role in cancer (Table 1) .
With respect to the EphA/ephrin A subsystem, Saito et. al. (2004) noted that expression level of EphA2 had a statistically significant relationship with liver metastasis, lymphatic vessel invasion, and clinical stage. Alford et. al. (2007) found that transglutaminase-cross-linked ephrin A1 and A5 bound to EphA receptors and promoted invasion and migration of HeLa cells. Moreover, Iida et. al. (2005) reported that the poor prognosis of patients with AFP-producing hepatocellular carcinoma was partially caused by ephrin A1 expression, which induced expression of genes related to tumour cell growth, angiogenesis, invasion, and metastasis.
With respect to involvement of the EphB/ephrin B subsystem in invasion, a greater depth of investigation has occurred, resulting in both observational and mechanistic insight. Nakada et. al. (2004) demonstrated that EphB2-transfected glioma cells showed increased invasive behaviour both in vitro and in an ex vivo rat brain slice. Furthermore, glioma invasion was promoted by activation of EphB2 or inhibited by blocking EphB2. This invasive behaviour was revealed to be controlled through an EphB2/R-Ras signaling pathway (Nakada et. al., 2005) .
EphB4 was shown to confer survival and invasive properties in head and neck squamous cell carcinoma (Masood et. al., 2006) . Moreover, Alam et. al. (2007) reported that histoscores and mRNA levels of EphB4 and ephrin B2 significantly increased with clinical stages, dedifferentiation, and myometrial invasion in uterine endometrial cancer. Similarly, Takai et. al. (2004) noted that ephrin B2 and EphB4 expression were significantly associated with the presence of clinical stage, histological grade, and invasion to >1/2 myometrium in endometrial carcinomas. Currently, controversy surrounds the role of EphB4 in invasiveness and potential prognosis in breast cancer, since this receptor has been reported to act both as a tumour suppressor and a tumour promoter (Noren et. al., 2006; Noren and Pasquale, 2007) .
Aside from the observations described in endometrial carcinomas, ephrin B2 mRNA expression was further reported to be elevated in higher stage neoplasms and in patients with high-risk AMES in malignant thyroid cancer (Kebebew et. al., 2005) . Ephrin B2 was also visualized in the invasive front of malignant melanoma (Meyer et. al., 2005) .
In the case of the correlation of ephrin B1 and B3 expression with invasive properties in cancer, mechanistic insight has also been provided. For ephrin B1, tyrosine phosphorylation of this ligand promoted invasion of gastric scirrhous carcinoma cells both in vitro and in vivo (Tanaka et. al., 2007a) . Through the Takai et. al., 2004; Noren et. al., 2006; Masood et. al., 2006; Alam et. al., 2007 EphB6 breast cancer downregulation of EphB6 correlates with the most invasive aggressive cell line and may serve as a prognostic indicator in breast cancer Fox and Kandpal, 2004 use of multiple cell lines, including pancreatic cancer cells, it was demonstrated that the C-terminus of ephrin B1 was responsible for conferring the increased invasive properties through activation of matrix metalloproteinase-8 secretion (Tanaka et. al., 2007b) . For ephrin B3, increased expression was noted specifically in invasive glioma cells (Hoelzinger et. al., 2005) , and this elevated ephrin B3 expression accompanied by phosphorylation leading to signaling through Rac1 was identified as critically important to glioma invasion (Nakada et. al., 2006) .
It has been proposed that Ephs operate during tumour progression through uncontrolled re-emergence of their developmental cell guidance capacity, promoting tumour metastasis, invasion and neo-angiogenesis (Wimmer-Kleikamp and Lackmann, 2005) . Interestingly, some studies have noted a down-regulation of Eph receptor expression corresponding to an invasive phenotype in certain cancers. For example, Fox and Kandpal (2004) reported that decreased expression of EphB6, which was down-regulated in the most aggressive breast cancer cell line, was particularly important in invasiveness. Additionally, Guo et. al. (2006) observed that reduced expression of EphB2 paralleled invasion and metastasis in colorectal tumours. Moreover, Batlle et. al. (2005) also noted that loss of EphB2 in colorectal cancer correlated with degree of malignancy. Thus, researchers have chosen to focus on individual Ephs and ephrins in specific types of cancer when designing potential therapies, instead of working from a general model.
Therapeutic Implications
Based upon the observed differential expression of Eph receptors and their ephrin ligands in a wide variety of cancers, it is not surprising that components of this system have been flagged as potential therapeutic targets. One approach has been antibody targeting of Ephs identified as consistently upregulated in specific cancers, thus offering selective targeting of tumour cells while minimizing harm to healthy tissues. This method has been used to target EphA2 in breast cancer cells (Carles-Kinch et. al., 2002) and EphB2 in colorectal cancer (Mao et. al., 2004) .
Another approach is to use antagonistic peptides that display selective binding. This method has been used in the case of EphB2 (Chrencik et. al., 2007) and EphA2 (Koolpe et. al., 2002) . Recently, Yamaguchi et. al. (2007) engineered a vaccine using dendritic cells pulsed with EphA2-derived peptides that resulted in long-term antitumour immunity against a rechallenge with MC38 tumour cells in a murine colon cancer model.
Function-blocking soluble Eph receptors have also been used to interfere with tumour growth and properties. As with the peptide approach, this method has been demonstrated for both the EphA and EphB subclasses (Brantley et. al., 2002; Martiny-Baron et. al., 2004; Kertesz et. al., 2006; Yang et. al., 2006) . A recent encouraging result was reported by Dobrzanski et. al. (2004) who found that administration of EphA2/Fc profoundly inhibited the growth of primary tumours and the development of peritoneal, lymphatic, and hepatic metastases in a murine pancreatic ductal adenocarcinoma model. Interestingly, this approach was also employed from a ligand perspective by introducing soluble ephrin A1-Fc to suppress growth of EphA2-expressing gastric cancer cells (Nakamura et. al., 2005) .
Eph/ephrin-influenced cytoskeletal signal transduction pathways dealing with cell motility, tumour invasiveness and metastatic potential have also been investigated as therapeutic targets. Such flagged components have included FAK, CRK, Rho, paxillin, Cbl, and Grb4 (Surawska et. al., 2004) . Further understanding of the Eph/ephrin system will bring forth more candidate targets.
Summary
Due to the emergence of the Eph receptor/ephrin system as a contributor to cellular invasive behaviour, it is likely that this system will remain a high priority in oncology for the development of new therapies and treatments. For example, a currently underutilized approach is the use of RNA interference, the sequencespecific gene silencing induced by double-stranded RNA (Campbell and Choy, 2005) . Numerous studies have utilized RNA interference to explore the effect of an Eph or ephrin knock-down in vitro, but have yet to engineer a successful in vivo method for the treatment of cancer.
Further studies in the manipulation of the Eph receptor/ephrin system will aid in engineering cancer therapies and in elucidating the complexity and additional functional implications of the system.
